Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company specializing in human genetics and personalized products, announces the U.S. launch of its new MGT Plus methylation test. This launch, in collaboration with U.S. partner 10X Health, marks a significant expansion of their joint product pipeline and strengthens their international partnership in innovative genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It plays a critical role in key metabolic pathways, influencing the function and processing of various biological molecules, including vitamins and neurotransmitters. While commercially available tests typically analyze a limited number of relevant genes, MGT Plus covers a total of 27 genes, providing a more comprehensive picture of methylation processes across six interconnected biological pathways. These include energy and nutrient metabolism, stress and neurotransmitter regulation, as well as vascular, immune, and cellular health. This expanded scope offers more precise insights into key biochemical processes, enabling a deeper understanding of methylation-related metabolic pathways.
“With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health,” says Dr. Daniel Wallerstorfer, CEO of Novogenia AG.
The global direct-to-consumer testing market is experiencing robust growth, reaching approximately $4.7 billion in 2025 and projected to exceed $16.0 billion by 2033. The genetic testing sector is particularly dynamic, representing over 40% of the market today and making it the largest segment. North America leads this sector, accounting for around 50% of the global market volume in 2025. This growth is driven by increasing interest in personalized health information, prevention, and individually tailored health services.
Novogenia's expansion into the U.S. market with MGT Plus underscores the company's strategic focus on leveraging scientific innovation to meet the rising demand for personalized health solutions. By offering a more comprehensive methylation test, Novogenia aims to empower individuals and healthcare providers with actionable genetic insights, potentially improving preventive care and treatment outcomes. The collaboration with 10X Health is expected to facilitate broader access to these advanced genetic analyses, further integrating personalized medicine into mainstream healthcare.
For more information about Novogenia AG and its products, visit https://novogenia.com/novogenia-ag.
